Key references: Haematopoietic stem cell transplant patients

Cooley L, Dendle C, Wolf J, Teh BW, Chen SC, Boutlis C, et al. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Intern Med J 2014;44(12b):1350–63. https://www.ncbi.nlm.nih.gov/pubmed/25482745
Erard V, Guthrie KA, Varley C, Heugel J, Wald A, Flowers ME, et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 2007;110(8):3071–7. https://www.ncbi.nlm.nih.gov/pubmed/17515400
eviQ. Prophylaxis - antifungal [v.2]. Sydney: Cancer Institute NSW; Last reviewed: 1 Mar 2017. https://www.eviq.org.au/clinical-resources/side-effect-and-toxicity-management/prophylaxis-and-treatment/1604-prophylaxis-antifungal
eviQ. Prophylaxis - antiviral therapy for herpes simplex virus (HSV) and varicella zoster virus (VZV) [v.3]. Sydney: Cancer Institute NSW; Last reviewed: 20 May 2016. https://www.eviq.org.au/clinical-resources/side-effect-and-toxicity-management/prophylaxis-and-treatment/1795-prophylaxis-antiviral-therapy-for-herpes-si
eviQ. Prophylaxis - Pneumocystis jiroveci (carinii) in cancer patients [v.5]. Sydney: Cancer Institute NSW; Last reviewed: 22 Sept 2017. https://www.eviq.org.au/clinical-resources/side-effect-and-toxicity-management/prophylaxis-and-treatment/220-prophylaxis-pneumocystis-jiroveci-carinii
Fleming S, Yannakou CK, Haeusler GM, Clark J, Grigg A, Heath CH, et al. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014. Intern Med J 2014;44(12b):1283–97. https://www.ncbi.nlm.nih.gov/pubmed/25482741
Maertens J, Marchetti O, Herbrecht R, Cornely OA, Fluckiger U, Frere P, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 update. Bone Marrow Transplant 2011;46(5):709–18. <www.ncbi.nlm.nih.gov/pubmed/20661235
Schar F, Trostdorf U, Giardina F, Khieu V, Muth S, Marti H, et al. Strongyloides stercoralis: Global Distribution and Risk Factors. PLoS Negl Trop Dis 2013;7(7):e2288. https://www.ncbi.nlm.nih.gov/pubmed/23875033
Slavin MA, Heath CH, Thursky KA, Morrissey CO, Szer J, Ling LM, et al. Antifungal prophylaxis in adult stem cell transplantation and haematological malignancy. Intern Med J 2008;38(6b):468–76. <www.ncbi.nlm.nih.gov/pubmed/18588520
Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009;15(10):1143–238. <www.ncbi.nlm.nih.gov/pubmed/19747629
Yokoe D, Casper C, Dubberke E, Lee G, Munoz P, Palmore T, et al. Infection prevention and control in health-care facilities in which hematopoietic cell transplant recipients are treated. Bone Marrow Transplant 2009;44(8):495–507. www.ncbi.nlm.nih.gov/pubmed/19861984